Small-molecule inhibitors of protein-protein interactions: Progressing towards the dream

被引:1313
作者
Arkin, MR [1 ]
Wells, JA [1 ]
机构
[1] Sunesis Pharmaceut, San Francisco, CA 94080 USA
关键词
D O I
10.1038/nrd1343
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Protein-protein interactions have a key role in most biological processes, and offer attractive opportunities for therapeutic intervention. Developing small molecules that modulate protein-protein interactions is difficult, owing to issues such as the lack of well-defined binding pockets. Nevertheless, there has been important progress in this endeavour in recent years. Here, we use illustrative examples to discuss general strategies for addressing the challenges inherent in the discovery and characterization of small-molecule inhibitors of protein-protein interactions.
引用
收藏
页码:301 / 317
页数:17
相关论文
共 179 条
  • [101] A specific mechanism of nonspecific inhibition
    McGovern, SL
    Helfand, BT
    Feng, B
    Shoichet, BK
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (20) : 4265 - 4272
  • [102] A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening
    McGovern, SL
    Caselli, E
    Grigorieff, N
    Shoichet, BK
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (08) : 1712 - 1722
  • [103] UNRAVELING THE STRUCTURE OF IL-2 - RESPONSE
    MCKAY, DB
    [J]. SCIENCE, 1992, 257 (5068) : 412 - 413
  • [104] Allosteric inhibitors of inducible nitric oxide synthase dimerization discovered via combinatorial chemistry
    McMillan, K
    Adler, M
    Auld, DS
    Baldwin, JJ
    Blasko, E
    Browne, LJ
    Chelsky, D
    Davey, D
    Dolle, RE
    Eagen, KA
    Erickson, S
    Feldman, RI
    Glaser, CB
    Mallari, C
    Morrissey, MM
    Ohlmeyer, MHJ
    Pan, CH
    Parkinson, JF
    Phillips, GB
    Polokoff, MA
    Sigal, NH
    Vergona, R
    Whitlow, M
    Young, TA
    Devlin, JJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (04) : 1506 - 1511
  • [105] Mete A, 2003, IDRUGS, V6, P57
  • [106] THE SOLUTION STRUCTURE OF THE F42A MUTANT OF HUMAN INTERLEUKIN-2
    MOTT, HR
    BAINES, BS
    HALL, RM
    COOKE, RM
    DRISCOLL, PC
    WEIR, MP
    CAMPBELL, ID
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 1995, 247 (05) : 979 - 994
  • [107] Anti-integrin as novel drug-discovery targets: potential therapeutic and diagnostic implications
    Mousa, SA
    [J]. CURRENT OPINION IN CHEMICAL BIOLOGY, 2002, 6 (04) : 534 - 541
  • [108] Stable "zeta" peptides that act as potent antagonists of the high-affinity IgE receptor
    Nakamura, GR
    Reynolds, ME
    Chen, YM
    Starovasnik, MA
    Lowman, HB
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (03) : 1303 - 1308
  • [109] Inducible nitric oxide synthase: What difference does it make?
    Nathan, C
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (10) : 2417 - 2423
  • [110] Biology of the interleukin-2 receptor
    Nelson, BH
    Willerford, DM
    [J]. ADVANCES IN IMMUNOLOGY, VOL 70, 1998, 70 : 1 - 81